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WEEKLY-DOCETAXEL CHEMOTHERAPY FOR TAIWANESE PATIENTS
WITHMETASTATIC CASTRATE-RESISTANT PROSTATE CANCER
Cheng-Li Kao 1,2, Tai-Lung Cha 1, Guang-Haun Sun 1, Dah-Shyong Yu 1, Sun-
Yran Chang 1, Seng-Tang Wu 1. 1Division of Urology, Departments of Surgery,
Tri-Service General Hospital, National Defense Medical Center, Taipei,
Taiwan; 2Divisions of Urology, Department of Surgery, Taoyuan Armed
Forces General Hospital, Taiwan
Purpose: Based on the tax 327 phase iii trial, docetaxel-based chemo-
therapy is the standard ﬁrst-line treatment for castration-resistant pros-
tate cancer (CRPC); however, there is some heterogeneity in the use of this
agent in routine clinical practice. The aim of the present study was to
examine the patterns of docetaxel use in routine clinical practice at our
institution and to compare themwith docetaxel use in the tax 327 clinical
trial.
Materials and Methods: We reviewed charts of all metastatic CRPC pa-
tients treated with docetaxel 30 mg/m2 weekly for 2 weeks out of 3 and
daily prednisolone 5 mg twice daily between January 2006 and February
2014 in Tri-service general hospital.
Results: In the ﬁrst-line setting, 19 patients with CRPC received docetaxel.
The main reasons for initiating docetaxel were rising prostate-speciﬁc
antigen (98%) and progressive symptoms (77%) and patients received a
median of 4 cycles of treatment. The median follow-up period from
starting chemotherapy was 27.9 (range: 5.4-67.2) months. The PSA
response rate was 47.3%. Median survival was 15.7 months. The main
toxicities were anemia (57%) fatigue (26%) and neuropathy (10%) but grade
3 to 4 adverse event only happened in two patients(one is neutropenia and
another one is anemia). Initial PSA < 100 ng/mL, duration of hormone
therapy>12 months, patients receive re-challenge and higher accumula-
tion dose of DTX were associated with good prognosis.
Conclusion: In conclusion, we suggested that for Taiwanese mCRPC pa-
tients, DTX 30 mg/m2 weekly for 2 weeks out of 3 is an efﬁcient regimen
with relative low Gr 3 or 4 hematological adverse effect. But proper timing
and duration of DTX therapy for Taiwanese is still uncertain and further
research is needed.
IPD04:
PROGNOSTIC VALUE OF NEUTROPHIL-TO-LYMPHOCYTE RATIO AND
ESTABLISHMENT OF NOVEL RISK STRATIFICATION MODEL IN
CASTRATION-RESISTANT PROSTATE CANCER PATIENTS TREATED WITH
DOCETAXEL CHEMOTHERAPY
Yoshihiro Nakagami, Jun Nakashima, Yoshio Ohno, Makoto Ohori, Masaaki
Tachibana. Tokyo Medical University, Tokyo, Japan
Purpose: Docetaxel (DTX) therapy is the standard treatment for castra-
tion-resistant prostate cancer (CRPC). The present study was undertaken
to investigate independent prognostic factors and develop a stratiﬁcation
model of survival in CRPC patients treated with DTX therapy.
Materials and Methods: The present study included 101 CRPC patients
treated with DTX therapy from December 2003 to October 2013 in a
single institution. We used the combination of docetaxel (DTX), estra-
mustine phosphate (EMP) and hydrocortisone every 3 weeks. Associ-
ations of clinical factors with survival were analyzed using univariate
and multivariate analyses.
Results: The average number of treatment courses was 11. Median overall
survival (OS) time was 21 months. In univariate analyses, patients with
pain, impaired performance status, hemoglobin (Hb)  11 mg/dl, neutro-
phil-to-lymphocyte ratio (NLR)  2.6, lactate dehydrogenase  230 IU/L,
PSA (at the initiation of DTX therapy)  110 ng/ml, alkaline phosphatase 
650 IU/L and C-reactive protein (CRP)  2 mg/dl showed signiﬁcantly
lower survival rates than their respective counterparts. On the other hand,
bone metastasis, age, PSA doubling time and lymph node metastasis were
not signiﬁcantly associated with OS. Multivariate analysis showed that
presence of pain (hazard ratio [HR] 3.60, p ˂0.001), CRP 2mg/dl (HR 3.49,
p¼ 0.002), impaired performance status (HR 2.75, p¼ 0.004), Hb 11 mg/
dl (HR 1.93, p ¼ 0.021), and NLR  2.6 (HR 1.98, p ¼ 0.031) were inde-
pendent predictors of OS. Using these 5 statistically signiﬁcant variables,
patients were stratiﬁed into 3 risk groups: low (RR ¼ 1 e 3.60),intermediate (3.82 e 34.55), and high (34.68 e 132.03). The differences
among the three groups were statistically signiﬁcant.
Conclusion: Elevation of NLR was an independent prognostic factor as
were presence of pain, elevated CRP, impaired performance status and low
Hb and the combination of these factors can stratify OS risks in CRPC pa-
tients treated with DXT therapy. Our risk stratiﬁcation model may be
useful to identify patients with poor prognosis, who might be good can-
didates for innovative treatment.
IPD05:
BONE MINERAL DENSITY LOSS ON LONG-TERM ANDROGEN-
DEPRIVATION THERAPY (ADT) FOR THE PROSTATE CANCER PATIENTS
IN JAPAN
Yu Ogawa, Yuuki Matsui, Takehiko Nakasato, Kazuhiko Oshinomi, Jun
Morita, Michio Naoe, Kozo Fuji, Yoshio Ogawa. Showa University,
Department of Urology, Japan
Purpose: There are only few reports about bone mineral density loss on
long-term androgen-deprivation therapy (ADT) for the prostate cancer
patients in Japan. We measured bone mineral density (BMD) of the pros-
tate cancer patients who were undergoing ADT.
Materials and Methods: A retrospective study was performed to measure
bone mineral density (BMD) of 76 prostate cancer patients who under-
went ADT from 2004 to 20 in Showa University Hospital. BMD, Young
Adult Mean (YAM), T score and Z score were assessed every year. We
excluded patients with bone metastasis. The patients were followed for at
least one year and for at most ﬁve years.
We measured bone density of three parts (lumber spine, total hip, distal
radius).
Results: BMD in three parts were decreased after the start of ADT. Z score
decreased in the same way. BMD decreased in lumber spine and total hip
after initial three-year period, but loss of BMD stopped after three years.
Distal radius BMD decreased at ﬁve years later.
Conclusions: It is called that lumber spine and total hip are inﬂuenced by
degenerative change in Dual energy X-ray absorptiometry. So, it may be
thought that distal radius was suitable for an evaluation of BMD of the
patient who underwent long-term ADT for the prostate cancer.
IPD06:
CHARACTERISTICS OF ARSENIC-RELATED BLADDER CANCER: A STUDY
FROM NATIONWIDE CANCER REGISTRY DATABASE IN TAIWAN
Jian-Hua Hong, Chung-Hsin Chen, Ting-Chun Yeh, Yi-Sheng Tai, Yeong-
Shiau Pu. Department of Urology, National Taiwan University Hospital,
Taiwan
Purpose: To investigate the clinical and pathological characteristics of
arsenic-related bladder cancer.
Materials and Methods: From 2008 through 2011, 7699 patients with
bladder cancer were extracted from Taiwan Cancer Registry Database.
According to birth residency codes, the patients were further divided into 3
areas, including the core zone (CZ) (arsenic endemic areawith awell water
arsenic level of 350 to 1,100 ng/ml), zone 1 (Z1) (a well water arsenic level
of 350 ng/ml or greater but not a blackfoot disease endemic area) and zone
2 (Z2) (a well water arsenic level of less than 350 ng/ml). Clinico-patho-
logical characteristics and survival outcome were compared among the
groups.
Results: In this cohort, 119 (1.5%), 1145 (14.9%) and 6435 (83.6%) patients
were born in the core zone, and zones 1 and 2, respectively. CZ patients had
more high grade (80.9%, 69.9%, 63.0%) and high stage (stage II-IV: 52.8%,
38.1%, and 31.8%) tumors compared to Z1 and Z2 patients. Radical cys-
tectomy was infrequently performed in stage II (19.6%) and III (25.2%)
bladder cancer patients in Taiwan. CZ patients had signiﬁcantly shorter
overall and cancer-speciﬁc survival duration than did Z1 and Z2 patients.
Old age, female gender, higher grade, higher stage, and higher arsenic
levels were associated with both poorer overall and cancer-speciﬁc sur-
vival in the multivariate analysis of Cox-proportional model.
Conclusion: Patients with arsenic related bladder cancer may have poorer
tumor characteristics and decreased overall and cancer speciﬁc survival in
Taiwan.
